Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 147536-97-8
Drug Levels and Effects
Summary of Use during Lactation
A study in one patient taking bosentan during breastfeeding found very low levels in milk. Another woman breastfed her preterm newborn while taking bosentan and sildenafil with no adverse effects reported. Amounts ingested by the infant are far below doses given to treat infants and would not be expected to cause any adverse effects in breastfed infants.
Drug Levels
Maternal Levels. A woman breastfeeding her 21-month-old infant was taking 125 mg bosentan twice daily and 20 mg sildenafil 3 times daily to treat pulmonary arterial hypertension. She pumped three milk samples collected at home over 24 hours on days 637 and 651 postpartum. Bosentan milk concentrations ranged from 23.2 mcg/L at 10 hours after the morning dose to 86.1 mcg/L at 6 hours after the morning dose. The average steady-state milk concentration of bosentan was 49 mcg/L. The patient’s infant was breastfed 3 times daily. The estimated infant doses via milk on the two days were 0.29 and 0.60 mcg/kg in this partially breastfed infant. A fully breastfed infant might receive a dosage as high as 7.43 mcg/kg daily, which translate into a relative infant dose of 0.24%. This dosage would also be far below the infant therapeutic dosage of 4 mg/kg.[1]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A 23-year-old woman with congenital heart disease and pulmonary hypertension was treated during pregnancy with bosentan and sildenafil in unspecified dosages. These drugs and warfarin were continued postpartum. Her infant was delivered at 30 weeks by cesarean section and weighed 1.41 kg at birth. She nursed the infant in the neonatal intensive care unit for 11 weeks "with good outcome" according to the authors, but the infant died at 26 weeks from a respiratory syncytial virus infection.[2]
A woman breastfeeding her 21-month-old infant was taking 20 mg of sildenafil 3 times daily and 125 mg of bosentan twice daily to treat pulmonary arterial hypertension. The drugs were begun more than 6 months postpartum. The mother did not report any possible adverse effects, serious health problem or hospitalization of the infant in the period from birth until day 651 postpartum when the infant continued to be partially breastfed.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Nauwelaerts N, Ceulemans M, Deferm N, et al. Case report: Bosentan and sildenafil exposure in human milk - a contribution from the ConcePTION Project. Front Pharmacol 2022;13:881084. [PMC free article: PMC9240352] [PubMed: 35784689]
- 2.
- Molelekwa V, Akhter P, McKenna P, et al. Eisenmenger's syndrome in a 27 week pregnancy--management with bosentan and sildenafil. Ir Med J 2005;98:87-8. [PubMed: 15869069]
Substance Identification
Substance Name
Bosentan
CAS Registry Number
147536-97-8
Drug Class
Breast Feeding
Lactation
Milk, Human
Antihypertensive Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Comprehensive Update on Synthetic Aspects of Bosentan Derivatives.[Mini Rev Med Chem. 2023]Comprehensive Update on Synthetic Aspects of Bosentan Derivatives.Panchal J, Panchal A, Jain S, Jain PK, Dwivedi J, Sharma S. Mini Rev Med Chem. 2023; 23(12):1238-1256.
- Review Sildenafil.[Drugs and Lactation Database (...]Review Sildenafil.. Drugs and Lactation Database (LactMed®). 2006
- Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.[J Pharmacol Exp Ther. 1994]Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W. J Pharmacol Exp Ther. 1994 Jul; 270(1):228-35.
- Review Tezacaftor and Ivacaftor.[Drugs and Lactation Database (...]Review Tezacaftor and Ivacaftor.. Drugs and Lactation Database (LactMed®). 2006
- Review Zaleplon.[Drugs and Lactation Database (...]Review Zaleplon.. Drugs and Lactation Database (LactMed®). 2006
- Bosentan - Drugs and Lactation Database (LactMed®)Bosentan - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...